The advertisement promotes CABOMETYX (cabozantinib) tablets as a treatment option for specific types of pancreatic neuroendocrine tumors in patients aged 12 and older. It highlights the importance of understanding potential serious side effects.
Creative Information
| CID: | c7c88ea6-7cc6-4136-abdc-bda1e2b397c7 |
| CRID: | 82_6157-850375 |
| Domain: | exelixis.com |
| Seat: | PP |
| Size: | 300x250 |
| Bid: | $1.43 |
| Timestamp: | 11/7/2025, 5:32:03 PM |
| Declared IAB Categories: |
Analysis
5 succeeded(100% complete)
| Task | Status | Last Updated | Duration | Actions |
|---|---|---|---|---|
| ad_analysis | success | 11/7/2025, 8:01:11 PM | 7.19s | |
| adomain_analysis | success | 11/7/2025, 8:41:15 PM | 4.80s | |
| adomain_capture | success | 11/7/2025, 8:41:10 PM | 0.09s | |
| ad_render | success | 11/7/2025, 8:01:04 PM | 24.58s | |
| brand_mapping | success | 11/7/2025, 8:41:11 PM | 1.34s | |
Analysis Results
Ad Format: banner
Brands: Exelixis
Sensitive:Pharmaceutical Products
Quality:Adomain not match landing page domain
| Size: | 300x250 | ||||||||||||||||||||||
| Data Transferred: | 1689.41 KB | ||||||||||||||||||||||
| Render Time: | 9.13 Seconds | ||||||||||||||||||||||
| Creative Inferred IAB Categories: |
| ||||||||||||||||||||||
| Creative Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Domain Inferred IAB Categories: |
| ||||||||||||||||||||||
| Domain Inferred IAB Ad Products: |
| ||||||||||||||||||||||
| Landing Page: | |||||||||||||||||||||||
| Total Ad Size: | 1695.11 KB | ||||||||||||||||||||||
| Requests Made: |
|
Advertiser Domain

Ad Preview
Landing Page

Creatives
